Adult stem cell therapy-neurological disorders - NeuroNova AB
Latest Information Update: 01 Nov 2005
At a glance
- Originator NeuroNova AB
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 01 Nov 2005 Discontinued - Preclinical for Neurological disorders in Sweden (unspecified route)
- 23 Jun 2004 Preclinical trials in Neurological disorders in Sweden (unspecified route)